Knowledge Hub
Featured content
01
Blog
Higher-dose and larger-volume subcutaneous therapies are creating new possibilities for drug delivery, including programs exploring the transition from intravenous (IV) to subcutaneous (SC) administration. A 2024 systematic review identified 182 clinical-stage or approved large-volume SC biopharmaceuticals, defined by the authors as doses greater than 2 mL, spanning oncology and a range of chronic disease areas.
Learn more
Blog
Beyond the Device: Key Takeaways from PDA PFS 2026
The 2026 PDA Universe of Pre-Filled Syringes and Injection Devices Conference brought the drug delivery community together in Palm Springs around the theme, “Where Molecules Meet Devices: Advancing Patient-Centric Solutions.” Across the program, the intersection of drug delivery, device development, combination products, technology and user experience was front and center.
Learn more
Resource
Download Noble’s Integrated Advantage Report
Download the report to discover how pharmaceutical organizations can move beyond fragmented execution and create a stronger foundation for launch success, patient confidence, and long-term therapy adherence.
Learn more
Blog
Device Differences Matter: Why Addressing Negative Transfer Is Critical to Biosimilar Success
As biosimilar and interchangeable biologic therapies continue to expand patient access to treatment, the industry has an opportunity to focus on more than affordability and availability. The patient experience must remain a priority, particularly as new delivery devices enter the market.
Learn more
Blog
What an Entrepreneurial Mindset Means in Pharma and Medical Device Development
Innovation is a constant in pharma and medical device development. But what separates true industry leaders is not just innovation—it’s an entrepreneurial mindset.
Learn more
News
Noble Advances Patient-Centered Innovation with New AI-Powered Sound Detection Patent
As healthcare continues its shift toward home-based care and self-administration, ensuring patients can use complex drug delivery devices correctly has never been more important. To support this evolving landscape, Noble, an Aptar Pharma company, has been awarded a new U.S. patent for an artificial intelligence-enabled method that uses sound recognition technology to help determine whether a drug delivery or diagnostic device has been operated correctly.
Learn more